The Week in Review: Shenzhen Hepalink Completes Big IPO

Shenzhen Hepalink Pharma, a heparin drugmaker, staged a 5.9 billion RMB ($868 million) IPO on the Shenzhen exchange; the company gained as much as 27% from its IPO price in its first trading session; S*BIO Pte Ltd. expanded its collaboration with Onyx Pharma in a $20 million deal; Kunwu Jiuding Capital invested 110 million RMB ($16.2 million) in Shanxi PowerdonePude Pharma; Roche will continue implementing its high-end pharma strategy in emerging markets; Hutchison MediPharma began a Phase I clinical trial of an anti-cancer drug; Actavis, a global producer of generic drugs, opened a regional office in Beijing; Sinovac Biotech (北京科兴生物制品有限公司) applied to begin clinical trials of a mumps vaccine; and Evonik Industries, an API company based in Germany, opened a new plant in Nanning, Guanxi province. More details… Stock Symbols: (NSDQ: ONXX) (VX: ROG) (AIM: HCM) (NSDQ: SVA)